Illumina Ventures

The firm manages around $500M. That capital backs Illumina Ventures's thesis across AI companies — from early-stage rounds through growth-stage follow-ons.

Illumina Ventures concentrates on AI, Genomics, Health. That focus has shaped a portfolio of companies building at the intersection of these areas.

Illumina Ventures has backed at least 1 AI companies that Awaira tracks. Venture portfolios often include undisclosed bets, so the true count could be larger.

Most of Illumina Ventures's capital goes into Early Stage rounds. This stage preference aligns with their fund structure and return expectations.

Among Illumina Ventures's portfolio, the standout deal is Illumina Ventures is a early-stage venture capital firm founded in 2016, headquartered in USA, managing approximately $500M in assets under management. The firm concentrates on AI, Genomics, Health, deploying capital primarily at the early stage level. Notable AI portfolio companies include Insilico Medicine. Illumina Ventures has participated in 1 funding round tracked by Awaira, deploying capital across AI, Genomics, Health sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Illumina Ventures an investor score of 58/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Illumina Ventures evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including Insilico Medicine reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.. This investment reflects the firm's broader strategy and risk appetite in the AI market.